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Abstract
Background: There is little published guideline or evidence on treating bipolar affective disorder
in patients with renal failure having haemodialysis.
Case:  We present two patients with bipolar affective disorder with renal failure having
haemodialysis. We used lorazepam in one patient to manage the immediate risk of non-engagement
with dialysis. Risperidone was added in the second patient for managing psychotic symptoms.
Valproate was started as a mood stabiliser and titrated upwards for long-term management of the
illness.
Conclusion: We discuss the similarities in the two cases and the care plan we used to manage
them.
Background
Improvements in life expectancy and quality of life in peo-
ple with chronic medical disorders means new challenges
are being created for clinicians. Two decades back chronic
renal failure was almost a death knell for patients but
today haemodialysis has led to increased life expectancy
and increased expectations of patients from their clini-
cians. For mental health professionals, the increased inci-
dence of psychiatric illnesses in those with chronic
illnesses, as well as the increased life expectancy of those
with renal failure means that we have to prepare ourselves
for treatment of mental health problems in renal failure.
While the kidneys are not functioning, and haemodialysis
has taken over the renal function, how do we adapt our
treatment and manage the concurrent social and health
issues.
We present two patients both admitted to an inpatient
psychiatric unit, with thrice-weekly haemodialysis and
present the treatment challenges and the different needs
of these individuals.
Case 1
A 47-year-old male patient, with end stage renal failure
(due to obstructive uropathy) and receiving haemodialy-
sis (for over an year), was admitted. He was known to
mental health services and was under a community men-
tal health team. He had been discharged from the inpa-
tient psychiatric unit, two months back, on olanzapine 20
mg at night, which he was partially compliant with.
He had been disruptive and aggressive at the dialysis
clinic. He was impatient and often asked for the dialysis to
be stopped before the process was over (usually 4 hours).
Staff, at his residence, also noticed him to be sleeping less,
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and not maintaining his diet and fluid restriction. He was
often pacing in the common area of the residence and
speaking loudly and angrily.
On mental status examination, he was loud, verbally
aggressive, demanding and uncooperative. There was
flight of ideas, pressure of speech and elevated mood. He
understood that he needed dialysis but was overcritical of
the time it took for the procedure. The immediate issue to
be addressed was facilitating dialysis. Since he consented
to having dialysis, the plan was to calm him down so as to
allow the entire process to be completed without undue
distress to the patient or to others. Olanzapine was rein-
stated and staff members from the inpatient psychiatric
unit accompanied him. He would still be loud, abusive
and demanding but would be calmer on verbal de-escala-
tion by staff.
On reviewing his history, a diagnosis of bipolar affective
disorder was made and valproate semi sodium started.
Valproate has a known role as a mood stabiliser; it is not
excreted by the kidney and is affected minimally by
haemodialysis in therapeutic concentrations [1]. Dose
was gradually (over a period of two weeks) increased to 2
gm per day. Predialysis level was 118 mg/l and 98 mg/l on
two occasions. Lorazepam was added at 1 mg twice/day.
A further dose of 2 mg before dialysis was prescribed to
help the client be calm when in the dialysis room. The use
of lorazepam on the morning of dialysis, helped substan-
tially as it was easier to complete the dialysis. After two
weeks on valproate 2 gm/day, he was noticed to be calm,
friendly, and pleasant. The report from dialysis clinic was
that he was sleeping throughout the procedure and was
not posing any problems at all. Lorazepam was gradually
withdrawn over ten days though a single 2 mg dose was
given before dialysis. After a further week without regular
lorazepam, the predialysis lorazepam was reduced to 1
mg and then stopped a week later.
No fluctuation was observed in his mental state between
the days of haemodialysis and the days when he did not
have haemodialysis.
Case 2
A 44-year-old female patient, known to be suffering from
bipolar affective disorder, had been well on lithium for
many years. Four years after being on high dose of lithium
(1000–1200 mg), consistently high serum lithium levels
were noticed. Lithium was tapered down to 200 mg over
the next three years. At this stage her urea and creatinine
were noticed to be high (urea 10.0 mmol/L, creatinine
345 umol/L). An oral dose of 200 mg lithium daily was
resulting in serum lithium levels of 1.16 mmol/L. Hence,
lithium was discontinued and valproate semi sodium
added at a dose of 500 mg bd. Peritoneal dialysis was
started, but was replaced by haemodialysis after one year.
Over these years she had also been receiving lofepramine
140 mg as an antidepressant for emergent symptoms of
grief, inability to cope and tiredness. Her renal failure led
to a reduction of the dose to 70 mg a day. Valproate was
also reduced to 250 mg bd, though the reasons for this are
not clear.
She had not needed hospitalization in a psychiatric unit
for over 14 years. Recently however, she presented to acci-
dent and emergency (A&E) three times within a week with
different complaints and physical symptoms, feeling
stressed and being fed up of dialysis. She was admitted to
the psychiatric unit after her fourth presentation to A&E.
Valproate was increased to 750 mg. On admission, she
was difficult, demanding, critical and disruptive. She tried
to leave the hospital and refused dialysis. She was
detained under the mental health act. During dialysis, she
would often shout, 'this is not my machine', 'you are tak-
ing all of my blood', or 'I am fed up of this dialysis'.
Within the psychiatric unit, she was labile in mood, ele-
vated at times and tearful at others. She continued to
express a desire to leave the hospital and not to take med-
ication or have dialysis. Valproate was increased to 1 gm
and risperidone was added 1 mg twice a day. Lofepramine
was stopped. After four days valproate was increased to
1250 mg daily. She improved within two weeks, became
less demanding, calm at dialysis and agreeing to be in hos-
pital.
Discussion
Renal failure and subsequent haemodialysis restores
physiological function for many patients and for many
years. Life expectancy for individuals on haemodialysis is
increasing especially when they are less than 50 years old
[2]. How does it impact on patients with mental health
problems? How do psychiatrists titrate the treatment of
such patients? This is a new area of psychiatry and the two
case reports present similar challenges managed by val-
proate.
Diagnosis
Both the patients had a diagnosis of mental illness before
chronic renal failure set in and before haemodialysis was
started. The first patient had been on the psychiatric ward
a few weeks before this presentation and discharged, as he
was well. The second patient was being managed by the
community mental health team (CMHT) for over four-
teen years, with a mood stabiliser and an antidepressant.
During this episode, a possibility of a mixed episode was
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Symptoms
Both patients were distressed with dialysis though they
understood that it was a life saving procedure. It is note-
worthy that despite the nature and degree of mental
health problems, both had not missed any appointment
for dialysis. The time it takes during the process was diffi-
cult for both patients; and during their exacerbations a
common theme was of demanding to be released off dial-
ysis sooner than the complete four/three hours respec-
tively. This is in keeping with the increased psychomotor
activity seen in mania.
Blood investigations
Patients on dialysis have monthly blood tests during the
dialysis procedures and this eliminated the need for the
ward to arrange for blood tests. It was arranged for copies
of the reports to be sent to us.
Pharmacological treatment
Treatment was chosen to be valproate as it is metabolised
in the liver and only 1% is excreted through the kidney
[1]. Dosage adjustments are not required in renal failure
[3]. It is thus a safe choice to prescribe for an individual
with renal failure.
Haemodialysis clears toxins that are < 500 g/mol, are
water soluble, have small volumes of distribution, follow
single compartment kinetics and are poorly bound to
plasma proteins. Valproate is a small (144 Da), water-sol-
uble molecule with a volume of distribution of only 0.1–
0.4 l/kg. However, at therapeutic doses it is 90–95%
bound to plasma proteins [1,4]. At toxic doses, the plasma
protein binding decreases (as a percentage) and it no
longer demonstrates single compartment kinetics. Hence,
haemodialysis is now recommended in valproate over-
dose [1]. Although haemodialysis has been shown to
reduce the level of valproate, but this has not been a sub-
stantial difference at therapeutic levels [1]. There is how-
ever, no guideline on using valproate as a therapeutic tool
while a patient is on haemodialysis.
The other two mood stabilisers lithium and car-
bamazepine were not considered because of renal failure
being a relative contraindication. A review of treatment of
patients with bipolar disorder and medical comorbidity
[5], suggested use of lithium in a patient on haemodialysis
[6] in a single post-dialysis dose of 300–600 mg and dis-
cussed a case report of intraperitoneal lithium during
CAPD [7]. Carbamazepine is to be avoided due to reduced
clearance of its toxic metabolite [5].
The first case also highlights the relative lack of efficacy of
olanzapine alone in maintaining remission. The use of
lorazepam in him is a treatment modality we successfully
used. It worked well helping the dialysis process to pro-
ceed as scheduled while the mood stabiliser was titrated
and had a therapeutic effect. Lorazepam is not recom-
mended in renal failure, but haemodialysis has been
found to reduce the peak plasma concentration, Tmax and
half life [8], thus posing no increased risk.
In the second patient we chose to add risperidone, due to
congruent psychotic symptoms. Risperidone is not recom-
mended in renal failure [5] and there is no data on its use
in a patient with haemodialysis. We therefore kept the
daily dose as low as was necessary to achieve clinical
response.
Nursing need
During hospital stay, a staff member was identified who
would accompany the patient to the dialysis unit. This
was to ensure that the dialysis process was not impeded or
missed. This staff member was trained in verbal descala-
tion of the patient while in the dialysis unit and on the
machine itself.
Patients on renal failure and having haemodialysis are
managed by diet restrictions and medication that reduces
the toxins that accumulate in the body. These additional
components of our patients' management meant develop-
ing a specific nursing care plan and carefully overseeing
the implementation of this plan. Changes to medication
and responding to concerns of the renal physician and
other health professionals was also required. A printed
information booklet was kept in the ward office for all
staff to familiarise themselves with renal failure, dialysis
and renal transplant.
Discharge planning
The first patient was living in 24 hr supported accommo-
dation, but after two admissions, they were reluctant to
have him back. While we attempted to resolve the con-
cerns of the staff and management of the supported hous-
ing, we also had to search for other options. A trained
worker was provided for accompanying him to dialysis
three times a week, from his supported accommodation.
The second patient had strong family support and
involvement. They were very happy to have her back.
Transplant list
The first patient has not been included on a transplant list,
because of concerns about his capability to monitor and
manage medication, and the prognosis of his mental
health problem. The second patient was on a transplant
list but was taken off it, due to her hospitalization in a psy-
chiatric unit. We are still trying to resolve this issue.
Conclusion
Patients with bipolar disorder and renal failure having
haemodialysis require treatment in a psychiatric inpatientPublish with BioMed Central    and   every 
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unit to be tailored to their unique needs. We have pre-
sented two cases that were managed with almost similar
care plans and medication. It is hoped that other mental
health professionals faced with similar patients will find
our approach informative and will contribute to the pub-
lished literature on this challenging clinical scenario.
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